This study analyzed whether therapy with CAMEL, an antimicrobial peptide (KWKLFKKIGAVLKVL), possess anticancer benefits. Although the peptide was cytotoxic for all the cell lines tested, it did not cause hemolysis, which suggests that CAMEL does not damage cell membranes. After cellular internalization, CAMEL localized to mitochondria and lowered the mitochondrial potential, resulting in the organelles' swelling, a decrease in cellular ATP level and, finally, cellular breakdown. High mobility group box 1 (HMGB1) protein, a necrotic death marker, was shown to be released from cells treated with CAMEL. Growth of B16-F10 melanoma tumors was clearly restrained after injections with CAMEL and could be kept in check throughout the period of peptide administration. However, if therapy was stopped, tumors started to grow again 3-4 days later. To reduce tumor volume and block tumor relapse, a combined therapy was required involving CAMEL and plasmid DNA carrying the interleukin-12 (IL-12) gene. The two therapeutic agents used in combination (a series of CAMEL injections first, followed by daily administration of plasmid DNA) delayed tumor growth and extended survival of treated animals in a statistically significant manner. Complete tumor regression was found in 60% of cases.
Recent data indicate that antimicrobial peptides can be useful for anticancer therapeutic purposes. 1 Such peptides consist of a dozen to a hundred of amino acids and are positively charged. 2 They are isolated from microorganisms and certain insect, plant, fish, reptile, bird or mammalian cells, including human cells. Some of these peptides are synthetic.
Antimicrobial peptides are part of a congenital, nonspecific and evolutionarily ancient form of immune response to various pathogens. 2 In several species such peptides are synthesized continuously, for example, in the hemolymph of insects or by cells of the vertebrate immune system. Some of these peptides, however, can be synthesized de novo as a result of contact with a specific pathogen. Antimicrobial peptides kill eukaryotic cells by destroying their cell membranes or mitochondrial membranes. 1 As a result of differences in cell membrane structure, larger surface area and the presence of villi, neoplastic cells are penetrated by antimicrobial peptide more selectively than normal cells. 3 The advantages offered by these highly specific substances, together with ease of synthesis and possibility of amino acid modifications, facilitate the design of novel peptides with desired therapeutic properties. 4 Thanks to their small size, such peptides are capable of deeply penetrating target tissues. 5 In addition, suitably designed and constructed peptides can feature sequences that allow peptide binding to respective cellular targets in a highly specific manner. 6 One of the shortcomings of these peptides is their limited circulation lifetime. A short linear peptide is rapidly degraded, with its halftime in the blood not exceeding 2-5 min. Longer peptides are more stable and have lifetime exceeding 1 to 2 h. 4 Additional therapeutic benefit of using peptides instead of whole proteins stems from the fact that peptides are less immunogenic.
The major aim of this study was to evaluate anticancer potential of an antimicrobial peptide named CAMEL. 7 This construct, abbreviated as CA(1-7)M(2-9), is made up of two fragments. One is derived from cecropin A (amino acids CA (1-7)), a peptide occurring in Hyalophora cecropia hemolymph and the other from melittin (amino acids M (2-9)), a peptide from Apis mellifera (honeybee). CAMEL is an antimicrobial compound active against both Gram-positive and Gram-negative bacteria and is more potent than either of its components separately. The hybrid peptide has no hemolytic activity, unlike melittin. We were also interested in the effects that CAMEL exerts upon specific eukaryotic cells in culture and in testing its therapeutic efficacy against experimental murine melanoma tumors. To test the prevention of tumor relapse we also evaluated a regimen of combined anticancer therapy based on the use of CAMEL and interleukin-12 (IL-12) gene-carrying plasmid DNA.
MATERIALS AND METHODS
Peptide Synthesis CAMEL (KWKLFKKIGAVLKVL-NH 2 ) and control peptide (YGWVLNESTILIFPK-NH 2 ) were synthesized using 9-fluorenylmethoxycarbonyl solid-phase chemistry. 8 The peptide was purified by solid-phase extraction on Kromasil sorbent (C8, 5 mm, 100 Å ) using the protocol described elsewhere. 9 The purity of resulting fractions (495-97%) was verified by using reversed-phase HPLC. The peptide was further analyzed for its physical-chemical properties using matrix-assisted laser desorption ionization time-of-flight mass spectrometry (MALDI-TOF).
Peptide Cytotoxicity
Cultures of B16-F10 murine melanoma, RENCA murine renal carcinoma, 4T1 murine mammary carcinoma, WM1158 human melanoma, NIH3T3 murine fibroblasts, Wi38 human fibroblasts as well as HECa10 and HEC PP murine endothelial cells were subjected to MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) test to determine the number of surviving cells after treatment with CAMEL. The cells were plated in 96-well NUNCLONt Surface (NUNCt) vessels (3-5 Â 10 3 cells/well) using RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and were incubated under standard conditions (37 1C/ 5% CO 2 , relative humidity 95%). After 24 h, the growth medium was replaced with fresh medium containing various concentrations of CAMEL and control peptide (1-20 mM, in quadruplicate). Fresh medium without peptide was added to controls. The plates were incubated for additional 24 h. Next, after medium removal, 100 ml of MTT solution (0.5 mg/ml in PBS À ) was added to each well and plates were incubated for 3 h at 37 1C. Subsequently, 100 ml of 0.125% HCl in isopropanol was added to each well. To assess the percentage of live cells in samples, absorbance (l ¼ 570 nm) was read using EL x 800 spectrophotometric plate reader (Bio-Tek Instruments).
Erythrocyte Hemolysis after CAMEL Administration
Blood samples were collected from C57BL/6 strain mice using Vacutainer K2E test tubes containing EDTA (Becton Dickinson). The samples were then centrifuged and the morphotic elements rinsed twice with PBS À (Dulbecco's PBS without Ca 2 þ and Mg 2 þ ions). A 10% erythrocyte suspension was incubated with increasing doses of CAMEL peptide (1-100 mM). PBS À was used as negative control and 1% Triton X-100 in water as positive control, respectively. The samples were centrifuged after incubation at 37 1C (30 min, 2 h and 24 h) and supernatants transferred into a 96-well plate to assay erythrocyte lysis (spectrophotometric reading at l ¼ 405 nm).
Release of Lactate Dehydrogenase (LDH) from Murine Melanoma Cells
The cells were plated in 96-well NUNCLON Surface (NUNC) vessels (4 Â 10 3 cells/well) using RPMI-1640 medium supplemented with 10% FBS and were incubated under standard conditions (37 1C/5% CO 2 , relative humidity 95%). Next, culture medium was switched to medium containing CAMEL (f.c. ¼ 2.5 and 10 mM), with the exception of controls to which only fresh culture medium was added. For each group, experiments were carried out in triplicate. After 5, 10, 30, 60 and 120 min the culture medium was collected and centrifuged. Aliquots (50 ml) of the media were then incubated with 50 ml Reaction Buffer (CytoTox 96 Non-Radioactive Cytotoxicity Assay kit, Promega). After 30-min incubation (RT) of light-protected samples, a 50 ml Stop Solution was added to each well of the 96-well plate. Absorbance (l ¼ 490 nm) was read using EL x 800 spectrophotometric plate reader (Bio-Tek Instruments). Cells treated with Lysis Solution were used as positive control. The released LDH was also measured for cells not treated with the peptide (background control) as well as in the medium alone. Cytotoxicity of the peptide was determined vs reference (Lysis Buffertreated cells, 100%).
Cellular Localization of CAMEL
To localize CAMEL in treated cells, a fluorescein isothiocyanate (FITC)-peptide conjugate was used (synthesized by GenScript). B16-F10 murine melanoma cells (2 Â 10 5 ) were plated in 3-cm dishes and left overnight. Next, culture medium in wells was switched to medium containing FITC-conjugated CAMEL (10 mM) and propidium iodide (0.5 mg/ml). Pictures of cell cultures were taken every 2 min using Nikon Eclipse 80i fluorescent microscope equipped with FITC and TRITC filters (see Supplementary Data).
To show specificity of CAMEL binding to mitochondria, the latter were isolated from liver according to a protocol described elsewhere. 10 In brief, livers were placed in a buffer (20 mM Tris pH 7.5, 10 mM KCl, 2 mM MgCl 2 , 1 mM DTT, 0.5 mM EDTA, pH 8.0, 5% glycerol), cut into pieces and homogenized with a teflon-type homogenizer. The homogenate was centrifuged twice at 800 g for 10 min at 4 1C and then at 10 000 g for 15 min at 4 1C. The pellet was washed with buffer, centrifuged again as above and finally resuspended in the buffer indicated above. The mitochondria were then incubated for 10 min with FITC-labeled CAMEL (5 mM) and MitoTracker Red CMXRos (Invitrogen) solution (500 nM) and flow cytometry analysis was performed (FACS Canto instrument, Becton Dickinson).
Determination of Mitochondrial Transmembrane
Potential B16-F10 murine melanoma cells were plated into six-well NUNCLON Surface (NUNC) dishes (5 Â 10 5 cells) using 3 ml culture medium per well. The cultures were left for 24 h in a standard incubator. Next, culture medium was switched to medium containing CAMEL (2.5, 5 and 10 mM) with the exception of controls to which fresh culture medium was added. After 3 h, the cells were gently trypsinized (trypsin/ PBS À 1:1 v/v) and resuspended in fresh medium. The samples were centrifuged (200 g for 2 min) and the pellets resuspended in PBS À (1 ml). Aliquots (10 ml) of JC-1 (5,5 0 ,6,6 0 -tetrachloro-1,1 0 ,3,3 0 -tetraethylbenzimidazolcarbocyanine iodide) dye (200 mM) were added to each sample. Cells not treated with peptide exposed to 2 ml of CCCP (carbonyl cyanide 3-chlorophenylhydrazone) were used as a positive control; CCCP strongly lowers the mitochondrial transmembrane potential. The samples were incubated for 15 min in a standard 37 1C incubator. Next, the cells were centrifuged (200 g, 2 min), the samples were washed (2 ml PBS À ), resuspended (0.5 ml PBS À ) and analyzed by flow cytometry (FACS Canto instrument). In living cells having high mitochondrial potential the JC-1 dye forms complexes emitting red fluorescence. In turn, dead cells are characterized by low mitochondrial potential. In such cells the JC-1 dye remains in monomeric state emitting green fluorescence. The percentage change of transmembrane potential was calculated (vs control set at 100%).
ATP Determination
B16-F10 cells were seeded (5 Â 10 5 cells/3 ml medium/well in six-well plates (NUNCLON Surface, NUNC) and cultured for 24 h. The growth medium was then replaced with medium containing CAMEL (2-10 mM). Fresh growth medium without peptide was used for controls. At the conclusion of incubation with CAMEL (30-180 min), the cells were trypsinized (0.4 ml/3 min, trypsin/PBS À 1:1 v/v) and resuspended in fresh medium. The samples were centrifuged (200 g for 2 min) and cell pellets resuspended in 1 ml PBS À and centrifuged again. The cells were recovered from the pellets and resuspended in 1 ml of lysis buffer (Promega), shaken for 10 s and centrifuged again (400 g for 1 min). The supernatant was collected, diluted 40-fold and 10 ml of the dilution was added to Standard Reaction Solution (90 ml) from the ATP Determination Kit (Invitrogen Molecular Probes). Oxyluciferin concentration was determined after measuring luminescence using a Lumat LB 9501 luminometer (Berthold). The protein content was assayed by Bradford method and sample luminescence was expressed as RLU/mg of protein.
Data from three separate measurements were used to calculate average values.
Electron Microscopy of CAMEL-Treated Cell Cultures B16-F10 cells were seeded (5 Â 10 5 cells/3 ml RPMI-1640 medium with 10% serum/well) in six-well plates (NUNCLON Surface, NUNC) and grown for 24 h. Growth medium was then replaced with medium containing CAMEL (5 mM), with controls receiving fresh growth medium. At the conclusion of incubation with CAMEL (30-180 min), the cells were trypsinized (0.3 ml/3 min, trypsin/PBS À 1:1 v/v) and resuspended in fresh medium. The samples were centrifuged (200 g for 5 min) and the cells were prepared for transmission electron microscopy according to a standard method, 11 with minor variations. In brief, cells were recovered from the pellet after a 5-min centrifugation at 200 g. Subsequently, the cells were fixed overnight at 4 1C (3% glutaraldehyde in 0.1 M phosphate buffer pH 7.4). The fixative was then removed and cells were washed and mounted in warm (45 1C) 2% agar solution. After polymerization, the agar-mounted specimens were cut into small cubes. The specimens were postfixed at 4 1C (2 h, 1% O S O 4 ), dehydrated in graded ethanol, submerged in propylene oxide and embedded in Epon 812 resin. The ultrathin sections were mounted on 300 mesh grids, stained with uranyl acetate and lead citrate and examined using JOEL JEM-100 CX transmission electron microscope at 80 kV. Therapy of Murine Melanoma Tumor-Bearing Mice with CAMEL C57BL/6 female mice (6-8 weeks old), bred and maintained in own animal facility, were used throughout the study. Permission from the local ethical committee of the Medical University of Silesia was obtained for all experiments. At 6 days after inoculation of mice with B16-F10 cells, when tumors reached ca. 5 mm in diameter, the mice were given intratumoral injections of a previously optimized dose of CAMEL or control peptide (YGWVLNESTILIFPK) (115 mg peptide/100 ml PBS À / animal) or 100 ml PBS À . CAMEL peptide was also administered intravenously (at 115 or 200 mg peptide/400 ml PBS À per animal). A total of three injections were performed. Each treatment group consisted of five mice.
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The effectiveness of therapy was monitored and determined based on measurable reduction of tumor growth rate.
In subsequent therapeutic experiments the mice were given intratumoral injections of higher dose of CAMEL (250 mg peptide/100 ml PBS À per animal). The peptide was administered daily for 5 consecutive days and then the therapy was interrupted for 5 days. When tumors resumed growth the sequence of CAMEL injections (as above) was repeated. In total, three such CAMEL sessions were completed. Animals from control groups received 100 ml of PBS À . Each treatment group consisted of five mice. The effectiveness of therapy was monitored and determined based on measurable reduction of tumor growth rate and prolongation of survival.
Immunohistochemical Analyses C57BL/6 mice were inoculated intradermally (dorsal side) with 2 Â 10 5 B16-F10 murine melanoma cells. When tumors reached ca. 5 mm in diameter, the mice received intratumorally two injections of CAMEL alone (115 mg/100 ml PBS À ) or CAMEL followed by nine injections of plasmid DNA carrying IL-12 gene (50 mg/100 ml). At 24 h after conclusion of injections, the tumors were excised, fixed in 2% paraformaldehyde (pH 7.2) and paraffin embedded. The tumors were then sectioned into 5-6-mm thick slices. The specimens were stained by hematoxylin and eosin (H&E). Necrotic areas were visualized using a Nikon 80i microscope. A similar experiment was performed using mice harboring 4T1 mammary carcinoma tumors. BALB/c mice were injected 4T1 cells (1 Â 10 5 ) and administered CAMEL (doses as indicated above) starting from day 6 after inoculation. Tumor sections were also incubated for 1 h with anti-HMGB1 rabbit antibody (Abcam) at 1:200 dilution. The unbound antibody was removed by rinsing the sections with PBS À . Horseradish peroxidase-conjugated anti-rabbit IgG (Vector Laboratories) was used as secondary antibody (1 mg/ml, 30 min). After rinsing with PBS À the sections were incubated with DAB. To visualize tumor structure the sections were stained with hematoxylin solution. Micrographs were taken and analyzed using Lucia software.
CAMEL and IL-12 Gene in Combination Therapy of Mice Bearing Experimental Melanoma Tumors
At 6 days after inoculation with tumor cells, C57BL/6 strain mice bearing experimental B16-F10 melanoma tumors were injected intratumorally with CAMEL (115 mg/100 ml PBS À per animal). The peptide was administered to mice on 2 consecutive days. Next, the animals received intratumoral injections of BCMGSNeo plasmid DNA (50 mg in 100 ml PBS À ) containing murine IL-12 gene. 12 DNA administration was continued daily for 14 days. After a 5-day pause the animals were again treated with CAMEL (three injections of 115 mg peptide in 100 ml PBS À ). Finally, another round of administration of plasmid DNA with IL-12 gene (50 mg in 100 ml PBS À for 14 consecutive days) was completed. Control mice received either plasmid DNA, or CAMEL or PBS À only. Figure 1 ). Control peptide was not toxic to B16-F10 cell line even at 50 mM concentration.
CAMEL does not Cause Erythrocyte Hemolysis
Fresh blood drawn from C57BL/6 mice was incubated with CAMEL (1-100 mM) for either 30 min, 2 h or 24 h. Under these conditions no significant change in the number of cells was observed, indicating lack of lysis. In addition, CAMEL administration was associated with insignificant increase in hemolysis. At peptide concentrations up to 10 mM, no changes could be shown compared with cells not treated with CAMEL. At 20 mM peptide the extent of hemolysis was increased by 5%, whereas at 40 mM the percentage of lysed cells was 17%, and reached 30% at 100 mM CAMEL (Figure 2 ). Thus, even at highest CAMEL concentration tested it did not cause the lysis of more than half of erythrocytes present. As positive control, 1% Triton X-100 in water was used; under normal conditions, this treatment results in complete lysis of red blood cells. At CAMEL concentrations toxic for B16-F10 cells the peptide did not cause erythrocyte hemolysis. In another experiment the LDH release from B16-F10 murine melanoma cells was analyzed. After CAMEL administration (at 2 or 5 mM), even after a 2-h incubation no significant differences were observed in the amount of LDH released. However, CAMEL administration at 10 mM did increase the amount of released LDH by 40% vs control after a 10-min incubation (data not shown). 
CAMEL Localizes in Mitochondria

CAMEL Causes Decrease in Mitochondrial Transmembrane Potential
Treatment with CAMEL caused a significant drop in mitochondrial membrane potential (directly dependent on peptide dose). At 2 mM, CAMEL caused the potential to drop to 75% (untreated control ¼ 100%); at 5 mM the potential dropped to 38.5% whereas at 10 mM the drop reached 29% of the control value ( Figure 4) . As positive control, a CCCP solution was used; this compound totally abolishes mitochondrial membrane potential in cells.
CAMEL Causes Drop in Cellular ATP Level ATP content was determined in cell lysates obtained from B16-F10 murine melanoma cells that were treated for 30-180 min with increasing amounts of CAMEL (2-10 mM). Addition of 2 mM CAMEL lowered within 180 min the ATP content by 40% when compared with control. Further increase of CAMEL concentration (5 mM) brought down the content of ATP to 30%, and, at 10 mM, to o20% ( Figure 5 ).
CAMEL Causes Swelling of Mitochondria
Transmission electron microscopy ( Figure 5 ) of B16-F10 murine melanoma cells treated with CAMEL (5 mM) show noticeable cell swelling after only a 30-min incubation in the peptide-containing medium. The swelling increased progressively from 30 to 180 min. Insets in Figure 6 micrographs show swelling of single mitochondria.
CAMEL does not Activate Caspase 3
The level of caspase 3 after CAMEL treatment was determined. At 5 and 10 mM concentrations, CAMEL did not activate caspase 3 within cells (Figure 7) . Caspase 3 was active in 7.1 and 5% of the cells examined, respectively. As positive control, camptothecin (6 mM)-treated cells were used; approximately 50% of these cells have activated caspase 3 and cells with active caspase 3 accounted for 8.6% of them. Tumor volumes in the groups receiving PBS and control peptide, when compared with the group receiving CAMEL, were significantly larger starting from day 9 of therapy (Po0.05), and reaching P ¼ 0.046 on day 16. Tumor growth was inhibited as long as administrations of CAMEL continued. If, however, the peptide-mediated therapy was interrupted, increased tumor volumes were noticeable after a couple of days. CAMEL was also administered intravenously (at 115 or 200 mg doses). After 13 days of therapy with 115 mg CAMEL, tumor growth was inhibited by 59% (compared with 96% in case of intratumoral administration). At 200 mg CAMEL the intravenous administration yielded a 76% growth inhibition (data not shown). Thus, therapeutic efficacy of intravenous administration did not match the intratumoral one.
To highlight the therapeutic potential of CAMEL, another sequence of its administration was used. First, mice received intratumoral injections of CAMEL (250 mg/100 ml PBS À ) for 5 consecutive days. The administrations were then discontinued and resumed after 5 days, when tumors had started growing again. In total, three such sequential sessions were accomplished. As a result, a significant inhibition of tumor growth was observed ( Figure 9 ). Again, tumor growth was restricted as long as CAMEL injections were continued. Tumor volume differences between the control group vs the CAMEL-receiving group were statistically significant from day 7 of therapy (Po0.05), and reaching P ¼ 0.0059 on day 18. After three consecutive series of peptide intratumoral CAMEL, a cancer therapy R Smolarczyk et al application, significant extension of animal survival was also observed (P ¼ 0.021). Tumor-bearing mice treated with CAMEL lived longer and in 20% of cases tumor regression was complete.
CAMEL Causes Tumor Necrosis, Restricts Tumor Growth and Triggers HMGB1 Protein Release from Cells
Mice bearing B16-F10 melanoma tumors ca. 5 mm in diameter were given intratumoral injections of CAMEL (115 mg/100 ml PBS À per animal) for 4 consecutive days. As a result, tumor volumes were decreased compared with control (PBS À ) (Figure 10a and b) . Histochemical specimens were prepared using tumor material from either non-treated (single dose of PBS To visualize the presence of HMGB1 cytokine (a necrotic marker) in the extracellular environment, sections prepared from murine melanoma tumors injected with CAMEL (115 mg per animal) were treated with an anti-HMGB1 antibody. The control sections revealed HMGB1 (stained brown) to be present mainly in cell nuclei (Figure 10e) , and also in the cytoplasm and outside of the cells. However, sections obtained from tumors treated with CAMEL revealed mainly cytoplasmic and extracellular HMGB1 presence, whereas minimal amount of brown staining was detected in nuclei, with the latter mostly stained with hematoxylin (Figure 10f ). 
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Combination of CAMEL and Plasmid DNA Carrying IL-12 Gene Inhibits Growth of B16-F10 Murine Melanoma Tumors Melanoma tumor-bearing mice received intratumoral injections of CAMEL (115 mg/1 ml PBS À ) for 2 consecutive days. For the next 14 days, the animals were injected intratumorally daily with BCMGSNeo plasmid DNA (50 mg/ 100 ml per animal) carrying the murine IL-12 gene. Upon completion of this protocol and an additional 5-day pause, the mice were treated again with three injections of CAMEL and then, for 14 days, again with the plasmid DNA. After the first round of CAMEL administrations, a significant tumor shrinkage was observed. However, during the subsequent period of plasmid DNA injections, tumors started regrowing. The mice were then subjected to the second round of CAMEL administrations and then to injections of plasmid DNA carrying the IL-12 gene. This strategy led to a significant reduction in tumor volumes compared with controls (mice treated with PBS À , CAMEL only, or plasmid DNA only; see Figure 11 ). The difference between tumor volumes in the group receiving CAMEL and in the group receiving both CAMEL and plasmid DNA with IL-12 gene was statistically significant from day 13 of therapy (Po0.05), and reaching P ¼ 0.02 on day 19.
Applying the above-described alternating mode of peptide/ plasmid administrations also resulted in a statistically significant extension of survival (P ¼ 0.018). The animals treated with CAMEL and IL-12-gene-carrying plasmid lived significantly longer than control. The therapy with two series of CAMEL and plasmid DNA administrations yielded complete tumor regression in 60% of animals.
H&E staining of tumor sections obtained from mice treated with CAMEL revealed that blood vessels were enlarged (red arrows). On the other hand, in tumors treated with CAMEL and plasmid DNA carrying IL-12 gene no such enlargement was found. In both cases leukocyte infiltration was present (blue arrows; Figure 12 ).
DISCUSSION
A number of naturally occurring antibacterial peptides show anticancer activity. As they are relatively easy to obtain and modify and show considerable therapeutic efficacy, such peptides are considered promising agents for novel anticancer therapies. Some of these peptides destroy neoplastic cells by disrupting their cell membrane whereas others cause destruction of mitochondrial membranes. 1 The compound CAMEL is a synthetic hybrid peptide, made up from cecropin A and melittin. 7 It seemed justified to test CAMEL in anticancer therapy as this peptide is capable of destroying cellular membranes, and mitochondrial membrane is believed to originate from endosymbiotic prokaryotes. We studied the mechanism of CAMEL effectiveness against cancer cells. We also evaluated the peptide's efficacy in the treatment of experimental melanoma tumors in mice, both singly and in combination with interleukin-12-encoding plasmid DNA, an immune-stimulating drug.
Compared with different antimicrobial substances showing anticancer properties, such as citropine (LC 50 ca. 50 mM), cecropin A and B (LC 50 ca. 20 mM) and magainine (LC 50 ca. 200 mM), 3 CAMEL kills neoplastic cells at lower concentrations. The lower effective dose of CAMEL has therapeutic implications as it reduces the probability of side effects that are often encountered during treatment.
CAMEL, the hybrid molecule of cecropin A and melittin, does not show hemolytic activity, which often accompanies were started on day 6 after inoculation of mice with B16-F10 cells, when tumors reached ca. 0.5 mm in diameter. The peptide was administered daily for 5 consecutive days, followed by a 5-day repose. When tumors started regrowing, therapy with CAMEL was resumed (next five injections, as above). In total, three sessions were completed. Each of the treatment groups had five animals. Graph shows the effect of peptide on tumor growth (arrows indicate peptide administration). The difference between tumor volume between the control group and the CAMELreceiving group was statistically significant from day 7 of therapy (*Po0.05) and reaching **P ¼ 0.0059 on day 18.
CAMEL, a cancer therapy R Smolarczyk et al with a single dose of CAMEL (115 mg/100 ml PBS À ). Paraffin-embedded tumors sections were also stained with anti-HMGB1 antibody. HRP-conjugated second antibody was then added and the preparation stained with DAB solution. HMGB1 protein is shown as staining brown. In addition, the sections were hematoxylin-stained. In control tumors (e) HMGB1 protein is shown to be localized in cell nucleus, whereas, after CAMEL administration, HMGB1 is detected in both cytoplasm and extracellular space (f).
CAMEL, a cancer therapyother peptide drugs, such as melittin or magainine. 3 Lysed red blood cells were found for melittin already at 0.78 mM, with 100% cell lysis occurring at 12.5 mM. 13 Only slight erythrocyte lysis is observed in case of CAMEL at 40 mM, whereas at 100 mM 30% of cells are affected after a 2-h exposure. This can suggest that CAMEL penetrates cells without affecting cellular membrane. No significant hemolysis of erythrocytes has been observed, even after a 24-h incubation. Studies with FITClabeled CAMEL and propidium iodide confirmed that the peptide penetrates cells and accumulates in the cytoplasm, and not in the nucleus. An increased number of cells with CAMEL peptide is observed within minutes. Nevertheless, as time elapsed, the ensuing cellular swelling and loss of membrane continuity led to red staining of cell nucleus with propidium iodide. In our opinion, after CAMEL administration and disruption of mitochondrial membranes, the loss of membrane continuity does take place in both normal and cancer cells. Disorganization of mitochondria triggers a significant drop in ATP, water influx and rupture of cells. This effect was not observed in erythrocytes that lack mitochondria. These results were corroborated with LDH release test. Administration of CAMEL at 2 or 5 mM concentration did not trigger LDH release; however, 10 mM CAMEL did increase the amount of LDH released. This suggests a loss of membrane continuity, but it is the result of mitochondrial damage, swelling and cells' rupture.
After internalization, CAMEL becomes localized on the surface of mitochondrial membrane. Because of positive charge, CAMEL strongly binds to negatively charged membranes of bacteria, mitochondria and some eukaryotic cells. This strong binding of peptidic drugs causes structural disturbances in the affected cells and ultimately leads to their destruction.
14 Using flow cytometric analysis with a lipophilic cationic substance, JC-1, we observed dissipation of mitochondrial transmembrane potential after treating B16-F10 cells with CAMEL, which causes mitochondrial swelling. It suggests that CAMEL destroys mitochondrial 15 postulated that CAMEL destroys bacterial membrane through a detergent-like 'carpet' mechanism or by channel formation disturbing ion gradient. According to these researchers, in aqueous solutions CAMEL does not adopt any definite structure, whereas upon attaching to the membrane it forms an a-helix that localizes ultimately within the lipid bilayer.
In the presence of CAMEL a progressive mitochondrial swelling (starting at ca. 30 min) was observed, which is possibly linked with a significant depletion of cellular ATP. In our experiments the amount of ATP was decreased already after 30 min of peptide administration, reaching values below 20% after 3 h. Depletion of ATP was proportional to the peptide amount added to samples. Lower ATP levels in the samples are indicative of cells undergoing necrotic type of death. 16, 17 Lower content of cellular ATP affects functioning of ion pumps (eg, potassium and calcium) and abolishes concentration-driven transport, which results in ionic imbalance in the cytosol and organelles. 18 Swelling leads to cell breakdown and results in cytosol spillout. These changes are typical of necrotic cell death.
The primary aim of this study was to analyze the therapeutic effect of CAMEL in mice harboring experimental B16-F10 melanoma tumors. The results indicate significant suppression of tumor growth already after a single peptide injection. No such effect was observed when control peptide was administered. However, tumor growth inhibition persisted only if peptide administration was continuous. After cessation of therapy with CAMEL, tumors resumed uncontrolled growth after 3 to 4 days, and hence the treated mice did not survive longer than the control mice. Intravenous administration of either 115 or 200 mg of CA-MEL yielded a much worse therapeutic effect than direct intratumoral administration of 115 mg of the peptide.
Subsequent to intratumoral administration of CAMEL, extensive necrosis was observed in tumor tissues, together with numerous foci of extravasated blood, which is suggestive of destroyed tumor vasculature. In contrast, H&E-stained sections of tumors from control mice revealed blood vessels and neoplastic cells evenly distributed around them. In untreated tumors, the HMGB1 protein, a necrosis marker, was mainly present in cell nuclei and, to a lesser extent, in the cytoplasm. 19 However, after CAMEL administration, HMGB1 protein was released from cell nucleus into cytoplasm and intercellular space. The release of HMGB1 protein causes ensuing inflammation because of the influx of lymphocytes, macrophages, neutrophils and mast cells, activation of defense mechanisms and repair of the affected tissue. [20] [21] [22] The cells of the immune system provide a variety of proangiogenic factors, as well as numerous cytokines and growth factors, and this together allows formation of new blood vessels and further tumor growth. 23 HMGB1 protein also activates migration of progenitor endothelial cell toward neoplastic cells. In addition, immune system cells stimulate invasiveness of neoplastic cells and their metastasis. 24 All of these events result in rapid tumor regrowth, which was indeed observed during this study when CAMEL therapy was interrupted.
To prevent tumor regrowth, three cycles of five CAMEL injections with intermittent 5-day pauses were examined. This protocol extended survival of treated animals. However, when administration of the peptide was ceased, tumor growth resumed rapidly.
To obtain a more persistent cessation of tumor growth and gain further prolongation of animal survival, we finally tried a combination of CAMEL and interleukin-12, an immunostimulatory drug. The main activity of the latter is to activate the differentiation of helper T lymphocytes into cytotoxic ones. IL-12 activates secretion of IFN-g that, in turn, stimulates proliferation of T lymphocytes and NK cells and activates their cytotoxic activities. 25 In addition, IL-12 inhibits formation of novel blood vessels, which is the key feature of tumor relapse. 26, 27 This occurs through IFN-g and specific interactions between lymphocytes and endothelial cells. Immunomodulatory and antiangiogenic functions of this protein make its use in anticancer therapy advantageous, especially when combined with major anticancer drugs, such as CAMEL. Combining administration of CAMEL and IL-12 gene-harboring plasmid, together with appropriate sequence of injections, allowed us to inhibit growth of experimental melanotic tumors in mice (completely destroyed tumors in 60% of the treated animals).
It seems therefore that specific combinations of necrosisinducing peptide (CAMEL) and IL-12-carrying plasmid DNA can inhibit tumor growth as well as prevent tumor relapse.
